Imatinib，又称伊马替尼，是可口服的2-苯胺嘧啶类的多靶点酪氨酸激酶抑制剂，作用于v-Abl、c-Kit和PDGFR的IC₅₀分别为0.6、0.1和0.1 μM，临床上用于治疗费城染色体阳性的慢性粒细胞白血病。

参考文献

[1] Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96(3):925-32(IF:16.562).

[2] Yao JC, Zhang JX, Rashid A, et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 1;13(1):234-40. doi: 10.1158/1078-0432.CCR-06-1618(IF:8.911).

[3] Sun XC, Yan JY, Chen XL, et al. Depletion of telomerase RNA inhibits growth of gastrointestinal tumors transplanted in mice. World J Gastroenterol. 2013 Apr 21;19(15):2340-7. doi: 10.3748/wjg.v19.i15.2340(IF:3.411).

[4] Ballinger ML, Ballinger ML, Hashimura K, et al. Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo. J Cell Mol Med. 2010 Jun;14(6B):1408-18. doi: 10.1111/j.1582-4934.2009.00902.x(IF:4.6580).

-25~-15℃保存，有效期3年。